Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
UpFrontPSMA
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
- NCT04343885 ↗
- Active, not recruiting
- Peter MacCallum Cancer Centre, Australia
- Focused
We haven't built an HCP commentary report on UpFrontPSMA (177Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on UpFrontPSMA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Hormone Naive Prostate Cancer
- Interventions
- 177Lu-PSMA-617; Docetaxel
- Arms
- 177Lu-PSMA+ Docetaxel · Experimental
- Docetaxel (Control) · Other
- Enrollment
- 130
- Primary outcomes
- Undetectable prostate specific antigen (PSA) rate at 12 months after commencement of protocol therapy
- Sponsor
- Peter MacCallum Cancer Centre, Australia with Movember Foundation, Prostate Cancer Research Alliance, United States Department of Defense, Advanced Accelerator Applications, Australia's Nuclear Science and Technology Organisation (ANSTO), Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australasian Radiopharmaceutical Trials network (ARTnet), Centre for Biostatistics and Clinical Trials (BaCT)
- Start
- Apr 21, 2020
- Primary completion
- Mar 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04343885 · updated Jul 11, 2025
Publications
linked from the registry- Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS; UpFrontPSMA Study Team. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024 Oct;25(10):1267-1276. doi: 10.1016/S1470-2045(24)00440-6. Epub 2024 Sep 15. PubMed 39293461